PEMIGATINIB (PEM i GA ti nib) treats bile duct cancer. It may also be used to treat a type of bone marrow cancer (myeloid/lymphoid neoplasm). It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.

PEMAZYRE Lifestyle Interactions

  • Pemigatinib 4.5mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Grapefruit or Grapefruit Juice during Pemigatinib treatment. Side effects from Pemigatinib may get worse if you take these drugs together. Your health care provider may need to adjust the dose of your medicine; do not adjust the dose by yourself. Contact your health care provider if you experience mouth sores, diarrhea, stomach pain, unusual tiredness or weakness, bone pain, changes in vision, or other new or unusual side effects.
    • Notes for Professionals: Instruct patients to avoid grapefruit or grapefruit juice during pemigatinib therapy due to the risk of increased pemigatinib exposure which may increase the risk of adverse reactions. Pemigatinib is a CYP3A4 substrate and grapefruit juice is a strong CYP3A4 inhibitor. Coadministration with another strong CYP3A4 inhibitor increased pemigatinib exposure by 88%.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.